| Serial Number | 88490321 |
| Word Mark | ELLIPSES PHARMA |
| Filing Date | Wednesday, June 26, 2019 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, December 21, 2021 |
| Registration Number | 6592661 |
| Registration Date | Tuesday, December 21, 2021 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 9, 2021 |
| Disclaimer with Predetermined Text | "PHARMA" |
| Goods and Services | Pharmaceutical preparations for the treatment of cancer; biological preparations for the treatment of cancer; anti-cancer preparations; anti-cancer drugs; compounds for treating cancer; biopharmaceuticals for the treatment of cancer, namely, antibodies, non-antibody proteins, blood and blood components, stem cells, hormones, blood factors, tumour necrosis factors; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-cancer preparations of microbial origin; pharmaceutical preparations for the treatment of cancer; anti-cancer preparations from hormones and antagonists; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer |
| Goods and Services | Medical and surgical apparatus and instruments, namely, instruments for diagnosing and treating cancer; medical analysis devices, namely, medical diagnostic devices for analyzing the presence or extent of cancer, and for monitoring cancer treatments, immunotherapy cancer treatments, radiation therapy cancer treatments, chemotherapy cancer treatments, radiotherapy cancer treatments, targeted cancer therapy treatments in the body, and for analyzing the efficacy of cancer treatments; medical imaging apparatus, namely, devices for cancer imaging; medical scanning apparatus namely, devices for scanning for cancer; apparatus for the diagnosis of cancer; apparatus for use in medical analysis for the diagnosis and treatment of cancer; cell counting units for medical diagnostic use, namely, electrical resistance cell counters, flow cytometers, and microscopic image analyzers; diagnostic apparatus for medical use for testing cancer cells; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer |
| Goods and Services | Medical and pharmacological research services; biological research, clinical research in the field of cancer and medical research; Providing an on-line network environment featuring technology that enables users to share data for drug and pharmaceutical research and development; Providing an on-line network environment featuring technology that enables users to share data in the field of the design, development and testing of drugs and pharmaceuticals; Providing scientific and technological services, namely, scientific research, analysis, and design relating to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer; design, development and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; laboratory research into new drugs and pharmaceutical products; pharmaceutical drug development services; research relating into medicines; consultancy services relating to scientific and medical research in the field of cancer and oncology; expert advice relating to drug development, namely consulting services in the field of drug development; laboratory analysis in the field of oncology; computer hardware and software design and development in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; computer network services namely providing search engines for obtaining information on a global computer network in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software hosting services, namely, hosting software for use by others for use in relation to medical databases and information, in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; software as a service (SAAS) namely, hosting software for use by others for use in relation to medical databases and information, in relation to oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to, cancer; Information Technology (IT) consultancy, advisory and information services relating to a network of medical research professionals in the technology field of medical information networks and databases; scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology and cancer clinical trials; scientific research projects and studies in the fields of oncology and clinical trials research; conducting clinical trials for others; clinical research in the field of oncology; clinical research in the field of cancer treatments and pharmaceuticals; providing an online network that features technology that enables users to share data for clinical trials; conducting and compiling data for others for research purposes in the field of treatment, cure and prevention of cancer via an online computer network; development of measuring and testing methods in the field of medicine; evaluation of pharmaceutical drug development services of others to assure compliance with industry standards; pharmaceutical product evaluation; pharmaceutical research services; all of the aforesaid in relation to in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer |
| Goods and Services | Medical services; medical consultation services; cancer consultation and treatment services, namely, medical diagnosis and treatment of cancer; health care services; health screening services in field of cancer; cancer screening services; managed health care services; pharmaceutical services namely, pharmaceutical advice; providing online medical record services, namely maintaining personal medical history records and files; advisory and consultancy relating to all of the aforesaid; all of the aforesaid for use in oncology, surgical oncology, radiation therapy, chemotherapy, hormonal therapy, immunotherapy, radiotherapy, targeted cancer therapy, and the prevention, diagnosis, treatment, management of, and/or surgery in relation to cancer |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, July 6, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials. |
| US Class Codes | 026, 039, 044 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, July 6, 2019 |
| Primary Code | 010 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, July 6, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Saturday, July 6, 2019 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Ellipses Pharma Ltd |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | London W1J6BD GB |
| Party Name | Ellipses Pharma Ltd |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | London W1J6BD GB |
| Party Name | Ellipses Pharma Ltd |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | London W1J6BD GB |
| Event Date | Event Description |
| Tuesday, December 21, 2021 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, November 17, 2021 | 1(B) BASIS DELETED; PROCEED TO REGISTRATION |
| Wednesday, November 3, 2021 | NOTICE OF ALLOWANCE CANCELLED |
| Wednesday, November 17, 2021 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Wednesday, November 3, 2021 | TEAS POST PUBLICATION AMENDMENT RECEIVED |
| Tuesday, May 4, 2021 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, March 9, 2021 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, March 9, 2021 | PUBLISHED FOR OPPOSITION |
| Wednesday, February 17, 2021 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, February 1, 2021 | ELECTRONIC RECORD REVIEW COMPLETE |
| Friday, January 29, 2021 | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED |
| Thursday, January 28, 2021 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, January 15, 2021 | NOTICE OF REINSTATEMENT E-MAILED |
| Thursday, January 7, 2021 | REINSTATEMENT GRANTED - INADVERTENTLY ABANDONED |
| Thursday, January 7, 2021 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Thursday, January 7, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Thursday, January 7, 2021 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Thursday, January 7, 2021 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Friday, January 8, 2021 | PREVIOUS ACTION COUNT WITHDRAWN |
| Wednesday, January 6, 2021 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Wednesday, January 6, 2021 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, January 6, 2021 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, January 6, 2021 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, January 6, 2021 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Monday, December 21, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, December 21, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Monday, December 21, 2020 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
| Tuesday, June 23, 2020 | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Tuesday, June 23, 2020 | FINAL REFUSAL E-MAILED |
| Tuesday, June 23, 2020 | FINAL REFUSAL WRITTEN |
| Friday, April 3, 2020 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, April 2, 2020 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, April 2, 2020 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 2, 2019 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, October 2, 2019 | NON-FINAL ACTION E-MAILED |
| Wednesday, October 2, 2019 | NON-FINAL ACTION WRITTEN |
| Tuesday, September 17, 2019 | ASSIGNED TO EXAMINER |
| Monday, September 9, 2019 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Thursday, September 5, 2019 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Thursday, August 1, 2019 | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED |
| Monday, July 29, 2019 | ASSIGNED TO LIE |
| Tuesday, July 23, 2019 | TEAS VOLUNTARY AMENDMENT RECEIVED |
| Saturday, July 6, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Saturday, June 29, 2019 | NEW APPLICATION ENTERED IN TRAM |